Journal Watch · Nature Reviews Clinical Oncology · 2026

Towards liquid biopsy-based analysis of antitumour immunity.

In this Review, we discuss insights on systemic antitumour immune responses that can be gained through the analysis of tumour-derived biomarkers in peripheral blood and/or circulating immune cells.

Pantel K, Masmoudi D, Alix-Panabières CNature Reviews Clinical Oncology3 min readPharma relevance 50/100

DOI: 10.1038/s41571-026-01181-8PMID: 42498740Study type: review / perspective

TL;DR

In this Review, we discuss insights on systemic antitumour immune responses that can be gained through the analysis of tumour-derived biomarkers in peripheral blood and/or circulating immune cells.

Key findings

  • Thus, blood-based analyses might complement tumour tissue analysis.
  • In this Review, we discuss insights on systemic antitumour immune responses that can be gained through the analysis of tumour-derived biomarkers in peripheral blood and/or circulating immune cells.

What they did

Technical advances have enabled multimodal analyses of cells and cellular products in peripheral blood samples, which can be obtained easily and repeatedly over the course of the disease. These liquid biopsy-based approaches cannot provide spatial information on the tumour immune microenvironment and tumour-derived material can be highly diluted in the circulation, yet they offer a unique opportunity to monitor systemic immune dynamics, anticipate responses to immunotherapies and detect emerging resistance to treatment.

Full abstract (original)

Background: Analysis of tissue biopsy samples is the gold-standard approach to cancer diagnosis and patient selection for biomarker-guided therapies. Although spatial analyses of tumour tissue can provide important insights into local antitumour immune responses, repeated tumour biopsy is invasive and rarely feasible for monitoring dynamic immune responses over time.

What they did: Technical advances have enabled multimodal analyses of cells and cellular products in peripheral blood samples, which can be obtained easily and repeatedly over the course of the disease. These liquid biopsy-based approaches cannot provide spatial information on the tumour immune microenvironment and tumour-derived material can be highly diluted in the circulation, yet they offer a unique opportunity to monitor systemic immune dynamics, anticipate responses to immunotherapies and detect emerging resistance to treatment.

Results & conclusions: Thus, blood-based analyses might complement tumour tissue analysis. In this Review, we discuss insights on systemic antitumour immune responses that can be gained through the analysis of tumour-derived biomarkers in peripheral blood and/or circulating immune cells.

Abstract © the authors / Nature Reviews Clinical Oncology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41571-026-01181-8 · PubMed 42498740.

Why it matters for pharma & biotech

  • Relevant to Pharmacology & Drug Discovery teams tracking Nature Reviews Clinical Oncology for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Nature Reviews Clinical Oncology study find?

In this Review, we discuss insights on systemic antitumour immune responses that can be gained through the analysis of tumour-derived biomarkers in peripheral blood and/or circulating immune cells.

What type of study is this?

It is a review / perspective, published in Nature Reviews Clinical Oncology in 2026. Technical advances have enabled multimodal analyses of cells and cellular products in peripheral blood samples, which can be obtained easily and repeatedly over the course of the disease.

Where can I read the original paper?

The original is at the publisher via DOI 10.1038/s41571-026-01181-8. PubMed ID: 42498740. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Pantel K, Masmoudi D, Alix-Panabières C. Towards liquid biopsy-based analysis of antitumour immunity.. Nature Reviews Clinical Oncology (2026). DOI: 10.1038/s41571-026-01181-8.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/towards-liquid-biopsy-based-analysis-of-antitumour-immunity-011818/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides